PMID- 10699437
OWN - NLM
STAT- MEDLINE
DCOM- 20000412
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 39
IP  - 5
DP  - 2000 Mar 3
TI  - Intracerebral transplantation of bone marrow with BDNF after MCAo in rat.
PG  - 711-6
AB  - We tested the hypothesis that a composite graft of fresh bone marrow (BM) along 
      with brain-derived neurotrophic factor (BDNF), transplanted into the ischemic 
      boundary zone (IBZ) of rat brain, facilitates BM cells to survive and 
      differentiate, and improves functional recovery after middle cerebral artery 
      occlusion (MCAo). The fresh BM was harvested from adult rats injected with 
      bromodeoxyuridine (BrdU) as a tracer. Rats (n=37) were subjected to 2h of MCAo, 
      received grafts at 24h and were sacrificed at 7days after MCAo. Test groups 
      consisted of: (1) control - MCAo alone (n=9); (2) injection of phosphate buffered 
      saline (n=4); (3) transplantation of BM (n=8); (4) injection of BDNF (n=7); and 
      (5) transplantation of BM with BDNF (n=9) into the IBZ. Immunohistochemistry was 
      used to identify cells derived from the BM stem cells. Behavioral tests (rotarod 
      motor test; adhesive-removal somatosensory test) were performed before and 7days 
      after MCAo. The data indicate that intracerebral grafting of a combination of BM 
      with BDNF enhances differentiation of BM cells and significantly improves motor 
      recovery of rotarod (P<0.05) and adhesive-removal (P<0.05) tests. We anticipate 
      that BM along with neurotrophic factors may provide a powerful autoplastic 
      therapy for human neurological injury and degenerative disorders.
FAU - Chen, J
AU  - Chen J
AD  - Henry Ford Health Sciences Center, Department of Neurology, 2799 West Grand 
      Boulevard, Detroit, MI 48202, USA.
FAU - Li, Y
AU  - Li Y
FAU - Chopp, M
AU  - Chopp M
LA  - eng
GR  - P01 NS23393/NS/NINDS NIH HHS/United States
GR  - R01 NS35504/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Antigens, Nuclear)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glial Fibrillary Acidic Protein)
RN  - 0 (Nuclear Proteins)
RN  - G34N38R2N1 (Bromodeoxyuridine)
SB  - IM
MH  - Animals
MH  - Antigens, Nuclear
MH  - Behavior, Animal/drug effects
MH  - Bone Marrow Cells/cytology/metabolism
MH  - Bone Marrow Transplantation/*methods
MH  - Brain/blood supply/*pathology/surgery
MH  - Brain Ischemia/pathology/therapy
MH  - Brain-Derived Neurotrophic Factor/*administration & dosage
MH  - Bromodeoxyuridine
MH  - Glial Fibrillary Acidic Protein/biosynthesis
MH  - Graft Survival/*drug effects
MH  - Immunohistochemistry
MH  - Infarction, Middle Cerebral Artery/*therapy
MH  - Injections, Intraventricular
MH  - Male
MH  - Nuclear Proteins/biosynthesis
MH  - Rats
MH  - Rats, Wistar
MH  - Recovery of Function/drug effects
EDAT- 2000/03/04 09:00
MHDA- 2000/04/15 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/04/15 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - S002839080000006X [pii]
AID - 10.1016/s0028-3908(00)00006-x [doi]
PST - ppublish
SO  - Neuropharmacology. 2000 Mar 3;39(5):711-6. doi: 10.1016/s0028-3908(00)00006-x.